Corvas' CEO Randy Woods Presenting To Investors At Philadelphia Healthcare/Biotech Forum Oct. 23.PHILADELPHIA--(BUSINESS WIRE)--Oct. 13, 1999--
If you thought malaria was a disease of the past, think again. Malaria remains a worldwide plague and is increasingly resistant to current therapies.
One company involved in research to eradicate this dreaded disease is Corvas International (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CVAS) of San Diego. Corvas is among five companies presenting at Informed Investors' Philadelphia Healthcare/Biotechnology Stocks Forum from 9 a.m.-1 p.m. at the Doubletree Hotel in Center City on Saturday Oct. 23. Cost is $25 prepaid. Register at www.informedinvestors.com or call 800-992-4683. Visit the website to learn how to listen to the Forum over the Internet.
CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Randy Woods of Corvas will present his company's initiatives on several fronts, including the design and development of new therapies for cardiovascular, cancer and other major diseases, including malaria. Woods will also brief investors on strategic collaborations with Pfizer (PFE), Schering-Plough (SGP), and Covance (CVD CVD Cardiovascular disease, see there ), and recent financing activities that added nearly $10 million to Corvas' cash position.
Corvas (www.corvas.com) was recently awarded a $600,000 grant from the National Institute for Allergy and Infectious Disease to support research into the discovery of protease inhibitors for prophylaxis and treatment of malaria, a disease that infects up to 500 million and kills 2.7 million people annually. New drugs are needed because current therapies are increasingly ineffective due to drug resistance in endemic areas, leading to a resurgence in malaria infection rates and associated morbidity and mortality Morbidity and Mortality can refer to:
On other fronts, Corvas' proprietary injectable anticoagulant anticoagulant (ăn'tēkōăg`yələnt), any of several substances that inhibit blood clot formation (see blood clotting). rNAPc2 is currently being tested in a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored
phase II for the treatment and prevention of deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. following orthopedic surgery. An additional Phase IIa trial in angioplasty is scheduled to begin later this year. Corvas has a strategic alliance with Pfizer to develop recombinant neutrophil inhibitory factor (rNIF) as a possible stroke therapy. Pfizer is currently conducting a Phase IIa trial of rNIF in patients suffering from acute ischemic stroke.
Corvas also has alliances with Schering-Plough to develop an oral anticoagulant for the prevention and treatment of chronic thrombosis and an inhibitor of a key protease associated with hepatitis C virus
In addition to Corvas, senior management from four other companies will be presenting as well: Integra LifeSciences (IART); AVAX Technologies (AVXT); Ribozyme Ribozyme
A ribonucleic acid (RNA) molecule that, like a protein, can catalyze specific biochemical reactions. Examples include self-splicing rRNA and RNase P, both involved in catalyzing RNA processing reactions (that is, the biochemical reactions that convert Pharmaceuticals (RZYM) and Lifemark (LMRK).
Alex Zisson, Managing Director and Senior Analyst/Pharmaceuticals at Hambrecht & Quist, is the keynote speaker. He will talk about biotech and healthcare companies. He covers the larger pharmaceuticals companies and has a special emphasis on the smaller, emerging drug companies and drug delivery.
Since 1993, Sacramento-based Informed Investors has featured hundreds of quality companies and scores of industry experts at its Forums.